Amy Roshak

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park, Eric B. Haura, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2021 · 632 citations · Full text

Medicine, Oncology, Pharmacology +17

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

Patricia L. Podolin, James F. Callahan, Brian Bolognese et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 299 citations

Medicine, Immunology, Pharmacology +17

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion–Driven NSCLC

Jiyeon Yun, Soo‐Hwan Lee, Seo-Yoon Jeong et al. · Cancer Discovery · 2020 · 288 citations · Full text

Medicine, Oncology, Pharmacology +17

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jeffrey R. Jackson, Aidan G. Gilmartin, Christina S. Imburgia et al. · PubMed · 2000 · 233 citations

Life Sciences, Cell Biology, Molecular Biology +17

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

Amy Roshak, Elizabeth A. Capper, Christina S. Imburgia et al. · Cellular Signalling · 2000 · 214 citations

Life Sciences, Cell Biology, Molecular Biology +15